Skip to main
TCRX
TCRX

TScan Therapeutics (TCRX) Stock Forecast & Price Target

TScan Therapeutics (TCRX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TScan Therapeutics Inc. has shown significant promise in its TCR-T therapy candidates, particularly TSC-100 and TSC-101, which demonstrated a 70% improvement in event-free survival (EFS) compared to the control group, alongside a notably low relapse rate of 8% versus 33% in the control arm. The company's ongoing efforts to expand its immunobank, including the recent IND filing for an additional MAGE-A4 TCR, position it to significantly increase the patient pool eligible for its multiplex therapies, particularly in the treatment of non-small cell lung cancer. Furthermore, TScan's robust pipeline, coupled with its progressive advancements in solid tumor programs, highlights a strategic focus on larger market opportunities, setting a strong foundation for long-term growth.

Bears say

TScan Therapeutics Inc reported a significant increase in net loss, amounting to $35.8 million, or ($0.30 per share) for the fourth quarter of 2024, compared to a loss of $19.6 million, or ($0.21 per share) in the same quarter of the previous year. The company's bear case scenario suggests a concerning outlook, with potential patient relapses in ongoing clinical trials for TSC-100 and TSC-101, which could lead to a substantial reduction in the probability of success for these therapies in hematologic malignancies. Furthermore, concerns about the company's ability to generate additional successful clinical candidates beyond its initial programs pose risks to its overall growth and valuation.

TScan Therapeutics (TCRX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TScan Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TScan Therapeutics (TCRX) Forecast

Analysts have given TScan Therapeutics (TCRX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, TScan Therapeutics (TCRX) has a Strong Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TScan Therapeutics (TCRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.